Repligen Co. (NASDAQ:RGEN) Shares Sold by Ameriprise Financial Inc.

Ameriprise Financial Inc. trimmed its stake in Repligen Co. (NASDAQ:RGEN - Free Report) by 2.6% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 929,090 shares of the biotechnology company's stock after selling 25,168 shares during the period. Ameriprise Financial Inc. owned about 1.66% of Repligen worth $133,733,000 as of its most recent filing with the SEC.

Several other large investors have also recently made changes to their positions in the stock. Signaturefd LLC raised its position in Repligen by 172.2% in the fourth quarter. Signaturefd LLC now owns 196 shares of the biotechnology company's stock valued at $28,000 after purchasing an additional 124 shares during the period. Sava Infond d.o.o. purchased a new stake in shares of Repligen in the 4th quarter valued at $29,000. Itau Unibanco Holding S.A. purchased a new stake in shares of Repligen in the 4th quarter valued at $40,000. UMB Bank n.a. lifted its stake in Repligen by 49.1% during the 4th quarter. UMB Bank n.a. now owns 334 shares of the biotechnology company's stock worth $48,000 after acquiring an additional 110 shares in the last quarter. Finally, Global Retirement Partners LLC boosted its holdings in Repligen by 54.0% during the 4th quarter. Global Retirement Partners LLC now owns 368 shares of the biotechnology company's stock valued at $53,000 after acquiring an additional 129 shares during the period. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Repligen

In related news, Director Margaret Pax bought 250 shares of the stock in a transaction dated Monday, March 17th. The stock was acquired at an average price of $150.69 per share, for a total transaction of $37,672.50. Following the acquisition, the director now owns 1,043 shares in the company, valued at approximately $157,169.67. This represents a 31.53% increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 1.20% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on RGEN shares. HC Wainwright reiterated a "buy" rating and set a $180.00 price target on shares of Repligen in a research note on Monday, May 5th. StockNews.com raised shares of Repligen from a "sell" rating to a "hold" rating in a research note on Thursday, May 8th. Evercore ISI assumed coverage on shares of Repligen in a research report on Tuesday, March 18th. They issued an "in-line" rating and a $155.00 price target for the company. Wolfe Research raised Repligen from a "peer perform" rating to an "outperform" rating and set a $160.00 price objective on the stock in a research report on Tuesday, April 29th. Finally, Royal Bank of Canada reduced their price objective on Repligen from $202.00 to $189.00 and set an "outperform" rating on the stock in a research note on Wednesday, April 30th. Six research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company's stock. According to MarketBeat.com, Repligen has a consensus rating of "Moderate Buy" and an average target price of $173.25.

Repligen Stock Up 0.4%

NASDAQ:RGEN traded up $0.49 during trading hours on Tuesday, hitting $134.21. The company's stock had a trading volume of 212,072 shares, compared to its average volume of 726,914. The stock has a market capitalization of $7.54 billion, a P/E ratio of -263.16, a price-to-earnings-growth ratio of 4.54 and a beta of 1.21. The company has a current ratio of 10.44, a quick ratio of 8.76 and a debt-to-equity ratio of 0.26. The stock has a fifty day moving average of $134.55 and a 200-day moving average of $145.43. Repligen Co. has a 52-week low of $102.97 and a 52-week high of $182.52.

Repligen (NASDAQ:RGEN - Get Free Report) last released its quarterly earnings data on Tuesday, April 29th. The biotechnology company reported $0.39 EPS for the quarter, beating analysts' consensus estimates of $0.35 by $0.04. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. The business had revenue of $169.17 million for the quarter, compared to the consensus estimate of $163.65 million. During the same quarter in the prior year, the business posted $0.28 EPS. The business's revenue for the quarter was up 10.4% on a year-over-year basis. On average, equities analysts forecast that Repligen Co. will post 1.72 earnings per share for the current year.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.